Skip to main content

Latest from Scripps Research

The people, discoveries and stories powering life-changing scientific breakthroughs.

For media inquiries, email us: [email protected]


Featured
Scripps Research scientists train the immune system to make antibodies against numerous HIV strains
News

Scripps Research scientists train the immune system to make antibodies against numerous HIV strains

Event background

The Front Row lecture series: Ryan Shenvi, PhD

Wednesday, August 19, 2026

4:00 - 6:00 PM PT

Enter curious, leave informed.

Event
Calibr-Skaggs advances CLF065, a regenerative GLP-2 therapy, into two Phase 2 IBD studies
News

Calibr-Skaggs advances CLF065, a regenerative GLP-2 therapy, into two Phase 2 IBD studies

CLF065, a long-acting, once-weekly GLP-2 receptor agonist, advances in two inflammatory bowel disease indications. The studies aim to bring a regenerative treatment option to patients living with IBD, who currently have few therapies that repair the damaged intestinal lining at the root of their disease.

Filter by:
Scripps Research scientists demonstrate a faster, cheaper route to making critical drugs using common table sugar
News

Scripps Research scientists demonstrate a faster, cheaper route to making critical drugs using common table sugar

New method illustrates how to build a tough chemical bond found in carbohydrate-based drugs, such as those for treating diabetes.

Calibr-Skaggs awarded $5.1M by NIH to develop long-acting hepatitis B virus therapy
News

Calibr-Skaggs awarded $5.1M by NIH to develop long-acting hepatitis B virus therapy

A new program aims to replace a daily HBV drug with once-monthly—or even quarterly—injections for people managing both HIV and HBV.

A fentanyl countermeasure that adapts to combat future black-market drugs
News

A fentanyl countermeasure that adapts to combat future black-market drugs

Scripps Research scientists developed a vaccine that teaches the immune system to rapidly neutralize fentanyl and new emerging synthetic fentanyl analogs.

Two Scripps Research assistant professors named 2026 Baxter Young Investigators
News

Two Scripps Research assistant professors named 2026 Baxter Young Investigators

The Baxter Foundation annually support early-career researchers whose work in science and technology holds promise for improving patient care.

Event background

The Front Row lecture series: Ryan Shenvi, PhD

Wednesday, August 19, 2026

4:00 - 6:00 PM PT

Enter curious, leave informed.

Event background

Angad Mehta, PhD

Monday, September 21, 2026

2:00 - 3:00 PM PT

Event background

The Front Row lecture series: Christian Diercks, PhD

Wednesday, October 14, 2026

4:00 - 6:00 PM PT

Enter curious, leave informed.

Event background

Christopher Walsh Memorial Lecture

Friday, October 23, 2026

2:00 - 3:00 PM PT


In the Media See all media
In the Media

Are we closer to understanding the origins of biological homochirality? 

Chemical & Engineering News

In the Media

Gray market peptides: So much hype, so little data 

Medscape

In the Media

Directly decorating double bonds 

Chemical & Engineering News

In the Media

Meet the winners of the 2026 Gairdner Awards 

The Globe and Mail


Science Changing Life Podcast See all episodes
scripps research science changing life podcast episode 45
Podcast

Donna Blackmond: Solving the origins of life and other mysteries in chemistry

Donna Blackmond never thought her career would lead to solving how life first formed on the prebiotic Earth. But as she points out in this episode of Science Changing Life, does any scientist start out knowing where their research will take them? Blackmond, who is a professor and the John C. Martin Endowed Chair in Chemistry at Scripps Research, shares how her wide-ranging background across chemistry and chemical engineering is helping answer some of today’s biggest questions in science and medicine.

scripps research science changing life podcast episode 43
Podcast

Ahmed Badran: Bioengineering our way out of climate change

Ahmed Badran is an assistant professor of chemistry at Scripps Research, where his lab harnesses synthetic biology to address some of biggest global problems. Listen in as we discuss reengineering plant enzymes to capture carbon, plastic-eating bacteria and new classes of antibiotics that spare our gut microbiome.

scripps research science changing life podcast episode 42
Podcast

Mia Huang: How sugar biology can help diagnose and treat cancer

Professor Mia Huang is based in the Department of Chemistry at Scripps Research, where her lab explores how vital sugar molecules in the body orchestrate complex biological events. Listen in as we discuss deciphering cancer cell signals to develop new therapies, engineering red blood cells for transfusions and how to become a master of strategy.

scripps research science changing life podcast episode 41
Podcast

Ram Krishnamurthy: Astrobiology, origins of life and the search for extraterrestrials

Professor Ram Krishnamurthy is based in the Department of Chemistry at Scripps Research, where his lab investigates the reactions that could have first given way to life on Earth. Listen as we discuss finding biological building blocks on meteorites, NASA’s search for life on other planets, and staying grounded with philosophy and meditation.

Expanding the drug target universe
Video

Expanding the drug target universe

There are countless proteins that play critical roles in disease, yet they remain challenging to target with therapeutics. In this Front Row lecture, Professor Benjamin Cravatt explained how his large-scale protein profiling research and innovative chemical technologies are helping identify novel drugs for therapeutic targets previously deemed ‘undruggable.’ Cravatt’s translational work, which is at the intersection of chemistry and biology, has also led to the formation of multiple local biotechnology companies that collectively employ hundreds of scientists who are developing first-in-class candidate medicines for diverse diseases ranging from cancer to neurological disorders.

Chemistry Drug Discovery Front Row Lecture Series
Regenerative medicine for the treatment of MS | Behind the Bench with Luke Lairson
Video

Regenerative medicine for the treatment of MS | Behind the Bench with Luke Lairson

Multiple sclerosis (MS) is a debilitating autoimmune disease that disrupts the central nervous system, causing symptoms like muscle weakness, cognitive challenges and a gradual loss of function that current treatments cannot fully repair. MS arises when the immune system attacks the myelin sheath, the protective layer insulating neurons. Scripps Research chemistry professor Luke Lairson discusses his research on the body’s natural repair pathways—specifically those that activate endogenous stem cells to restore myelin. His work aims to develop therapies that complement existing therapeutic approaches and halt MS progression.

Chemistry Autoimmune Diseases Behind the Bench multiple sclerosis Neurological Disorders
Regenerative medicine for the treatment of MS: Enhancing repair to prevent progression
Video

Regenerative medicine for the treatment of MS: Enhancing repair to prevent progression

Multiple sclerosis (MS) is a debilitating autoimmune disease that disrupts the central nervous system, causing symptoms like muscle weakness, cognitive challenges and a gradual loss of function that current treatments cannot fully repair. MS arises when the immune system attacks the myelin sheath, the protective layer insulating neurons. In this Front Row lecture, Scripps Research chemistry professor Luke Lairson discussed his research on the body’s natural repair pathways—specifically those that activate endogenous stem cells to restore myelin. His work aims to develop therapies that complement existing therapeutic approaches and halt MS progression.

Chemistry Autoimmune Diseases Front Row Lecture Series multiple sclerosis Neurological Disorders
Front Row spotlight with Luke Lairson
Video

Front Row spotlight with Luke Lairson

Multiple sclerosis (MS) is a debilitating autoimmune disease that disrupts the central nervous system, causing symptoms like muscle weakness, cognitive challenges and a gradual loss of function that current treatments cannot fully repair. MS arises when the immune system attacks the myelin sheath, the protective layer insulating neurons. Scripps Research chemistry professor Luke Lairson will discuss his research on the body’s natural repair pathways—specifically those that activate endogenous stem cells to restore myelin. His work aims to develop therapies that complement existing therapeutic approaches and halt MS progression.

Chemistry Autoimmune Diseases Front Row Lecture Series multiple sclerosis Neurological Disorders
Beyond the bench: Curiosity, creativity and chemistry with M. Reza Ghadiri
Magazine

Beyond the bench: Curiosity, creativity and chemistry with M. Reza Ghadiri

Ghadiri reflects on the formative moments that set him on his scientific path and influenced his unwavering commitment to making the impossible a reality.

Cross-coupling, radically simplified
Magazine

Cross-coupling, radically simplified

A new reaction developed by the Baran lab transforms simple building blocks into complex molecules with the clean release of nitrogen.

Christopher Parker Receives 2026 ACS Chemical Biology Early Career Award
Magazine

Christopher Parker Receives 2026 ACS Chemical Biology Early Career Award

Scripps Research professor Christopher Parker has been named the recipient of the 2026 American Chemical Society’s (ACS) Chemical Biology Early Career Award, which recognizes early-career investigators making an outsized impact on the field of chemical biology. It is jointly administered by the editor-in-chief of the ACS Chemical Biology and the ACS’s Division of Biochemistry and Chemical Biology and is reserved for researchers who have started their independent research positions within the last 10 years.

A vital antibiotic is failing. One chemist’s fix could work for centuries.
Magazine

A vital antibiotic is failing. One chemist’s fix could work for centuries.

Antibiotics are easy to take for granted—until they stop working. These medicines underpin much of modern healthcare, from routine surgeries to cancer treatments to the management of chronic conditions. Yet bacteria are increasingly developing resistance to our most trusted drugs, and the pharmaceutical pipeline for new antibiotics has slowed to a trickle due to a lack of financial incentive.

Groundbreaking Science.
Life-changing Medicine.